ASSOCIATION BETWEEN APOLIPOPROTEIN E POLYMORPHISMS AND EPILEPSY IN CHILDREN

Monika Kukuruzović1, Vanja Bašić Kes2 and Maša Malenica1

1Department of Pediatrics, University Hospital Center Sestre milosrdnice, Zagreb, Croatia; 2Department of Neurology, University Hospital Center Sestre milosrdnice, Zagreb, Croatia

SUMMARY – Apolipoprotein E (APOE) plays an important role in lipid metabolism and is a proven risk factor for development of dementia and other neurodegenerative diseases. The aim of the study was to determine the possible connection between particular APOE alleles, blood lipid profile and different types of epilepsy in children. Alleles of the APOE gene, blood cholesterol (total, high-density lipoprotein and low-density lipoprotein (LDL) cholesterol, and triglyceride levels were analyzed in blood samples of 111 children with epilepsy and 118 age- and sex-matched children without epilepsy. Distribution of APOE genotypes was the same in children of both groups. Significantly increased levels of total cholesterol and LDL cholesterol were found in control group (Z=3.49 and 3.52 respectively, p<0.01). No statistically significant difference was found between the genotypes of children with idiopathic and symptomatic epilepsy ($\chi^2=1.96; \text{df}=2; p>0.05$). There were statistically significant differences in the levels of total cholesterol (Z=2.09; p<0.05) and LDL cholesterol (Z=2.05; p<0.05) according to the type of epilepsy in favor of symptomatic epilepsy. The study confirmed that there was no connection between APOE and type of epilepsy in children and showed the children with epilepsy to have lower total cholesterol and LDL cholesterol levels. Interestingly, this also held true for children with idiopathic epilepsy compared to those with symptomatic condition.

Key words: Apolipoprotein E; Brain plasticity; Children with epilepsy; Gene polymorphism; Lipoprotein

Introduction

Epilepsy is a chronic disorder of the brain function with different etiologies, characterized by recurrent seizures caused by excessive electrical discharges and various clinical features and laboratory findings. Approximately 50 million people worldwide have epilepsy. Epilepsy has a prevalent occurrence in childhood, since 60% of all patients suffering from epilepsy are children under the age of 16. During the history, classification of epilepsy has greatly changed, and universal opinion has not been formed to the present day. We still use the International League Against Epilepsy (ILAE) classification system from 1989, which is compatible with the International Statistical Classification of Diseases and Related Health Problems, 10th Revision, officially in use by the Croatian Institute for Health Insurance. According to etiology, epilepsy can be classified as idiopathic (possibly hereditary, no neuro-radiologically visible neuroanatomic or pathologic abnormalities, no clearly defined genetic basis), symptomatic (secondary epilepsy, acquired or with confirmed brain lesion associated with anatomic and pathologic changes), and cryptogenic (symptomatic epilepsy is suspected, but no brain lesion has been confirmed). In symptomatic epilepsy, the cause can be identified and specific treatment can be applied, while in idiopathic epilepsy no definitive cause can be found. Epileptic seizures are the result of an abnormal and excessive activity and interaction of excitatory and inhibitory inputs from a number of neurons. This can lead to developmental abnormalities due to changes in distribution, transport, and movement of ions. All the above-mentioned processes can be regulated by apolipoprotein E (APOE). Therefore, it is possible that
Apolipoprotein E plays an important role in the occurrence and maintenance of epileptic seizures\textsuperscript{10-12}.

Apolipoprotein E is a glycoprotein engaged in the transport and metabolism of lipids in the entire body. It appears in three isoforms, ε\textsubscript{2}, ε\textsubscript{3} and ε\textsubscript{4}. APOE ε\textsubscript{3} allele is most common (70\%-80\%), followed by APOE ε\textsubscript{4} (10\%-15\%), and APOE ε\textsubscript{2} (5\%-10\%)\textsuperscript{12}. The APOE gene in humans is localized at 19q 13.2. Apart from the liver, which is the main organ for plasma lipoprotein synthesis, APOE is also synthesized in astrocytes and microglia of the brain. In the brain, it takes part in cholesterol distribution during repair, growth and myelination of the nerve cell membrane during development and aging. Hence, it plays an important role not only in brain injuries, either ischemic or traumatic, but also during epileptic seizures\textsuperscript{13,14}.

The studies published so far have described the connection of APOE isoforms and their plasma concentration with the occurrence of neurodegenerative diseases, especially Alzheimer’s disease. Analysis of the APOE alleles in patients suffering from Alzheimer’s disease showed a significant correlation between APOE allele type 4 and development of Alzheimer’s disease\textsuperscript{15-17}. An important connection of APOE polymorphism and outcome of head injury has been reported, with patients carrying APOE ε\textsubscript{4} being more likely to have unfavorable outcome 6 months after head injury as opposed to patients with other APOE isoforms\textsuperscript{2,18,19}. The authors studying the connection between epilepsy and APOE found a connection between APOE and early onset of temporal lobe epilepsy, as well as a higher risk of late post-traumatic seizures\textsuperscript{20,21}. However, to our knowledge, no study in children with different epilepsy etiology has been published so far. Epilepsy in children usually involves genetic/hereditary, unknown, metabolic, and structural changes in the brain, while acquired conditions such as head trauma, infection and cerebral stroke are rarely the cause. Considering the participation of apolipoprotein in the brain function and the plasticity of a juvenile brain, we examined the apolipoprotein genotype in childhood epilepsy patients in order to get earlier diagnosis and better therapeutic result\textsuperscript{18,22-24}.

**Patients and Methods**

The study included 254 children (131 female and 123 male) aged 2 months to 18 years, divided into the epilepsy group consisting of 111 children diagnosed with the condition, and the age- and sex-matched control group consisting of 143 children who were observed in our department due to the signs and symptoms other than epilepsy (e.g., vertigo, headache, syncope). In the control group, there were 71 girls and 72 boys, while in the patient group there were 60 girls and 51 boys. Patient characteristics are shown in Table 1. The study was conducted in the Division of Pediatric Neurology, Department of Pediatrics, Sestre milosrdnice University Hospital Center from October 2011 to January 2017. The patients underwent complete neurological examination. Classification of epilepsy was done according to the ILAE criteria from 1989.

**Table 1. Characteristics of patients with epilepsy and control subjects**

|                        | Patients with epilepsy | Control group |
|------------------------|------------------------|---------------|
| Subjects               | 111                    | 143           |
| Age (yrs)              | 9.58 (2-18)            | 10.86 (2-18)  |
| Gender (male/female)   | 51/60                  | 72/71         |

The study was approved by the Hospital Ethics Committee and performed in accordance with Helsinki Declaration. Informed consent was signed by parents or legal guardians of the children.

Peripheral blood was collected from all children. The blood samples collected were processed in the Clinical Department of Chemistry, Sestre milosrdnice University Hospital Center, where APOE genotyping and blood lipid profile was performed. Blood samples (5-7 mL) were collected in Vacutainer\textsuperscript{®} tubes (BD Diagnostics, Franklin Lakes, USA) with EDTA. Until DNA isolation, they were kept at -20 °C and were analyzed within a month. Leukocyte DNA for genotyping was isolated by the standard salting-out method. The mutation detection kit contained all classic components of the polymerase chain reaction (dNTP, Mg\textsuperscript{2+}, polymerase, primers, reaction buffer) and fluorescent probes complementary to the DNA segment located close to the polymorphism. Genotype detection is based on the melting curve analysis. The probes were perfectly complementary either to the wild-type sample or the sample with polymorphism. A computer program translates the signal to the curve with the
maximum at the melting temperature based on which the genotype is identified.

Plasma concentrations of cholesterol (total cholesterol, high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol), and triglycerides were determined from peripheral blood samples collected from all subjects using standard clinical practice after 18-hour fasting. Serum was obtained from whole blood without addition of anticoagulants (manufacturers of vacuum tubes, Greiner Bio-One, Austria) following centrifugation for 15 min at 3500 rpm. The instrument, or automatic analyzer was AU2700 (Beckman, USA) or Architect c8000 (Abbott, USA), depending whether the results were recorded before or after 2014. Until July 2014, we used Beckman, and since then Abbott instrument.

Standard reference range for plasma lipid concentrations was used to determine whether a patient had a low (below or within the reference interval) or high (above the reference interval) concentration of every biochemical parameter tested. Reference values were as follows: total cholesterol ≤5 mmol/L; HDL ≥1 mmol/L for females and ≥1.2 mmol/L for males; LDL ≤3 mmol/L; and triglycerides ≤2 mmol/L.

Data processing applied descriptive statistics. All statistical analyses were performed using SPSS version 13.0 statistical software (SPSS Inc., Chicago, IL, USA).

**Results**

There was no statistically significant difference in the observed and expected APOE genotype frequencies between the patients with epilepsy and control group (p=0.834), and it can be argued that the APOE gene polymorphisms were equally distributed in children suffering from epilepsy and in the general population. The highest proportion of alleles belonged to ε3/ε3 (50.0% to 62.9%) as wild-type, whereas the ε2/ε2 and ε4/ε4 alleles were 20-25 times smaller in size. However, there was a statistically significant between-group difference in the levels of total plasma cholesterol (Z=3.49; p<0.01) and LDL cholesterol (Z=3.52; p<0.01), i.e. control group subjects had higher total cholesterol and LDL cholesterol levels.

Distribution of particular APOE gene polymorphisms depending on the type of epilepsy did not differ significantly among the focal, generalized, and unclassified types of epilepsy (p=0.529). The distribution of individual APOE gene polymorphisms depending on the epilepsy subtype (focal idiopathic or symptomatic, generalized idiopathic or symptomatic, epileptic syndrome, unclassified) did not show significant differences (p=0.554) as neither did the distribution of individual APOE polymorphisms depending on symptomatic or idiopathic subtype of epilepsy.
The genotypes showed a correlation to plasma LDL levels (p=0.02). Depending on the type of epilepsy, there was a statistically significant difference in the levels of total cholesterol (Z=2.09; p<0.05) and LDL cholesterol (Z=2.05; p<0.05) in favor of symptomatic epilepsy. No statistically significant difference was found between the genotypes of children with idiopathic and symptomatic epilepsy ($\chi^2=1.96$; df=2; $p>0.05$). These results are shown in Figure 1.

The $\chi^2$-test used for genotype and Mann Whitney U test for cholesterol showed that there were no statistically significant relations between the genotype, HDL, type of the disease, and triglyceride levels in either group.

Discussion

Currently, there are only a few studies related to APOE in children. Our study showed that there was no difference in the genotypes of children with epilepsy compared to control group, similarly to previous studies performed in adult patients\(^{25-27}\). Those studies in adult patients also showed the APOE $\varepsilon$3/$\varepsilon$3 genotype to be most common in both groups, while $\varepsilon$2/$\varepsilon$2 was rarely present, which is consistent with our study. Interestingly, our control group had higher total and LDL cholesterol levels, in contrast to some earlier studies which showed total and LDL cholesterol levels to be significantly higher in subjects with epilepsy\(^{26,28}\). A possible explanation for this are different eating habits (e.g., in Croatia, both inland and Mediterranean cuisines are consumed). It is also interesting to note that genotypes showed a correlation to LDL levels and marginal correlation to total plasma cholesterol levels, although there were no differences in genotype frequencies between the patient and control groups. This may indicate that genotype is just one of the factors involved in the cholesterol turnover in epilepsy.

The possible limitations of this study were the inability to measure APOE concentration (higher APOE concentration is connected with higher levels of total and LDL cholesterol), and the fact that only a few subjects with some genotypes were examined.

Since both the etiology of epilepsy and the immature nature of the brain in children have a significant impact on the outcome of the disease, it is clear that APOE polymorphisms could have considerable effect on the type of epilepsy in children\(^{29}\). The results of our study did not show correlation between the APOE polymorphism and the type of epilepsy in children, which partly confirms some of the studies conducted on adults\(^{30,31}\). In previous studies, many authors tried to connect APOE with temporal lobe epilepsy and mesial hippocampal sclerosis. Some authors could not find any connection, which they attributed to the limited size of the sample, and concluded that only patients with the APOE $\varepsilon$4 allele might have an increased risk of developing epilepsy with mesial hippocampal sclerosis\(^{31}\). However, other authors report that patients having temporal lobe epilepsy have a larger concentration of APOE in plasma compared to controls. It was finally concluded that there was a connection between APOE and temporal lobe epilepsy\(^{26,27,31,32}\). In our study, we did not try to prove the correlation between APOE and temporal lobe epilepsy since the lesion itself is very rare in children\(^{33}\). Some studies showed a strong correlation between the APOE $\varepsilon$4 allele and epilepsy, most notably a study conducted on a population of the Han Chinese, but other studies disputed these results\(^{18,27,34}\). The APOE $\varepsilon$4 allele is a risk factor for intracellular accumulation of beta-amyloid which plays the key role in the increase of nerve cell sensitivity to damage. The presence of APOE $\varepsilon$4 reduces the ability of the brain to repair the damage and create new synapses. Therefore, it can be concluded that APOE is a gene potentially involved in synaptogenesis and that its polymorphisms can result in development of temporal lobe epilepsy\(^{35}\). The results of our study showed no correlation between particular alleles and type of epilepsy. The reason may be an insufficient number of subjects or interplay of other factors involved. Considering previous studies which failed to prove the connection between APOE and febrile convulsions and thus could not establish the fact that APOE affects the prognosis of febrile convulsions and further development of epilepsy, our results could be interpreted as an additional confirmation that there is no such connection in children\(^{36,37}\). Other studies on the role of epilepsy as a comorbidity in children with cerebral palsy and the connection with APOE report the same findings\(^{38}\).

Our study showed that subjects with symptomatic epilepsy had higher levels of total and LDL cholesterol compared to subjects suffering from epilepsy of an unknown cause. It is well known that cholesterol plays a significant role in synaptogenesis and is also
important for myelination and growth of membranes both during development and adulthood. Good regulation and impermeability of the blood-brain barrier is very important for this process. Cholesterol is mostly accumulated in the brain during perinatal development and adolescence, at the same time with myelination. When the myelination process ends, the concentration of cholesterol in the brain decreases and the level of cholesterol depends on external source. APOE in the brain parenchyma assists in the regulation of plasma lipids and metabolism of cholesterol. In case of damage to the cells of the central nervous system, APOE also plays an important role as a recovery factor in regeneration in some of the cells during re-myelination through redistribution of lipids. When the cholesterol reaches the maximum required level, 24-hydroxylase catalyzes cholesterol into 24S-hydroxycholesterol (24-OHC), which can be removed in the presence of HDL, and in this way protects the neurons from the toxic effect. High cholesterol and its damaged metabolism leads to imbalance which increases the risk of development of various conditions and diseases affecting the brain (Alzheimer’s disease, other neurodegenerative diseases, cerebrovascular diseases) and which may be a cause of symptomatic epilepsy. In vitro studies showed that cholesterol overload in plasma membrane resulted in the increase of amyloid-β in the primary neuronal culture. That is a pathologic marker for the occurrence of not only Alzheimer’s disease but also of other brain affecting diseases including epilepsy. Therefore, it is important to understand that inadequate cholesterol regulation can lead to changes in its distribution and transport, which is a basis for development of epileptic seizures and finally, epilepsy itself.

Finally, our research showed that APOE polymorphisms could not be strongly correlated to the occurrence of epilepsy or type of epilepsy in children and, therefore, they cannot be a predictive factor for the outcome of the disease.

References

1. Weber YG, Lerche H. Genetic mechanisms in idiopathic epilepsies. Dev Med Child Neurol. 2008;50(9):648-54. http://doi.wiley.com/10.1111/j.1469-8749.2008.03058
2. Teasdale GM, Nicoll JA, Murray G, Fiddes M. Association of apolipoprotein E polymorphism with outcome after head injury. Lancet. 1997;350(9084):1069-71. http://linkinghub.elsevier.com/retrieve/pii/S0140673697034318
3. World Health Organization. Epilepsy. 2018. https://www.who.int/news-room/fact-sheets/detail/epilepsy
4. Camfield P, Camfield C. Incidence, prevalence and aetiology of seizures and epilepsy in children. Epileptic Disord. 2015;17(2):117-23. http://www.ncbi.nlm.nih.gov/pubmed/2589550.
5. Chin JH. The global fund for epilepsy: a proposal. Neurology. 2013;80(8):754-5. http://www.neurology.org/cgi/doi/10.1212/WNL.0b013e31828250c5
6. Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia. 2010;51(4):676-85. http://doi.wiley.com/10.1111/j.1528-1167.2010.02522
7. Shorvon SD. The etiologic classification of epilepsy. Epilepsia. 2011;52(6):1052-7. http://doi.wiley.com/10.1111/j.1528-1167.2011.03041
8. Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia. 1989;30(4):389-99. http://www.ncbi.nlm.nih.gov/pubmed/2520238
9. Fisher RS, van Emde Boas W, Blume W, Elger C, Genton P, Lee P, et al. Epileptic seizures and epilepsies: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 2005;46(4):470-2. http://doi.wiley.com/10.1111/j.0013-9580.2005.66104
10. Laskowitz DT, Lee DM, Schmechel D, Staats HF. Altered immune responses in apolipoprotein E-deficient mice. J Lipid Res. 2000;41(4):613-20. http://www.ncbi.nlm.nih.gov/pubmed/10744782
11. Lynch JR, Morgan D, Mance J, Matthew WD, Laskowitz DT. Apolipoprotein E modulates glial activation and the endogenous central nervous system inflammatory response. J Neuroimmunol. 2001;114(1-2):107-13. http://www.ncbi.nlm.nih.gov/pubmed/11240021
12. Mahley RW, Rall SC. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet. 2000;1(1):507-37. http://www.annualreviews.org/doi/10.1146/annurev.genom.1.1.507
13. Dekroon RM, Armati PJ. Synthesis and processing of apolipoprotein E in human brain cultures. Glia. 2001;33(4):298-305. http://www.ncbi.nlm.nih.gov/pubmed/11246228
14. Pitas RE, Boyles JK, Lee SH, Foss D, Mahley RW. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim Biophys Acta. 1987;917(1):148-61. http://www.ncbi.nlm.nih.gov/pubmed/3539206
15. Gallardo G, Schlüter OM, Stüdhof TC. A molecular pathway of neurodegeneration linking α-synuclein to ApoE and Aβ peptides. Nat Neurosci. 2008;11(3):301-8. http://www.nature.com/articles/nn2058
16. Martins CAR, Oulhaj A, de Jager CA, Williams JH. APOE alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear model. Neurology. 2005;65(12):1888-93. http://www.ncbi.nlm.nih.gov/pubmed/16380608

17. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Englund J, Salvesen GS, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90(5):1977-81. http://www.ncbi.nlm.nih.gov/pubmed/8446617

18. Blackman JA, Worley G, Strittmatter WJ. Apolipoprotein E and brain injury: implications for children. Dev Med Child Neurol. 2005;47(1):64-70. http://www.ncbi.nlm.nih.gov/pubmed/15686292

19. Emmerich T, Abdullah L, Crynen G, Dretsch M, Evans J, Ait-Ghezala G, et al. Plasma lipidomic profiling in a military population of mild traumatic brain injury and post-traumatic stress disorder with apolipoprotein E ε4-dependent effect. J Neurotrauma. 2016;33(14):1331-48. http://online.liebertpub.com/doi/10.1089/neu.2015.4061

20. Brielmann RS, Torn-Broers Y, Busuttil BE, Major BJ, Kalnins RM, Olsen M, et al. APOE epsilon4 genotype is associated with an earlier onset of chronic temporal lobe epilepsy. Neurology. 2000;55(3):435-7. http://www.ncbi.nlm.nih.gov/pubmed/10932283

21. Diaz-Arrastia R, Gong Y, Fair S, Scott KD, Garcia MC, Carller MC, et al. Increased risk of late posttraumatic seizures associated with inheritance of APOE epsilon4 allele. Arch Neurol. 2003;60(6):818-22. http://archneur.jamanetwork.com/article.aspx?articleid=100010.1001/archneur.60.6.818

22. Aboud O, Mrak RE, Boop FA, Griffin WS. Epilepsy: neuroinflammation, neurodegeneration, and APOE genotype. Acta Neuropathol Commun. 2013;1(1):41. http://actaneurocomms.biomedcentral.com/articles/10.1186/2051-5960-1-41

23. Kurowski B, Martin LJ, Wade SL. Genetics and outcomes after trauma. J Pediatr Rehabil Med. 2012;5(3):217-31. http://www.ncbi.nlm.nih.gov/pubmed/23023254

24. Mauch DH, Nagler K, Schumacher S, Göritz C, Müller EC, Otto A, et al. CNS synaptogenesis promoted by glia-derived cholesterol. Science. 2001;294(5545):1354-7. http://www.ncbi.nlm.nih.gov/pubmed/11701931

25. Chhabra S, Agarwal DP, Vasisht S, Luthra K, Narang R, Manchanda SC, et al. Study of apolipoprotein E polymorphism in normal healthy controls from northern India. Dis Markers. 2000;16(3-4):159-61. http://www.ncbi.nlm.nih.gov/pubmed/11381199

26. Kumar A, Tripathi M, Pandey RM, Ramakrishnan L, Srinivas M, Luthra K. Apolipoprotein E in temporal lobe epilepsy: a case-control study. Dis Markers. 2006;22(5-6):335-42. http://www.ncbi.nlm.nih.gov/pubmed/17264404

27. Li Z, Ding C, Gong X, Wang X, Cui T. Apolipoprotein E ε4 allele was associated with nonlesional mesial temporal lobe epilepsy in Han Chinese population. Medicine (Baltimore). 2016;95(9):e2894. http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00005792-201603010-00034

28. Kortke BA, Moll PP, Michels V V, Weidman WH. Levels of lipids, lipoproteins, and apolipoproteins in a defined population. Mayo Clin Proc. 1991;66(12):1198-208. http://www.ncbi.nlm.nih.gov/pubmed/1749288

29. Wirrell E. Infantile, childhood, and adolescent epilepsies. Conti Lifelong Learn Neurol. 2016;22(1,Epilepsy):60-93. https://insights.ovid.com/crossref?an=00132979-201602000-00009

30. Blümcke I, Brockhaus A, Scheiwe C, Rollbrocker B, Wolf HK, Elger CE, et al. The apolipoprotein E epsilon 4 allele is not associated with early onset temporal lobe epilepsy. Neuroreport. 1997;8(5):1235-7. http://www.ncbi.nlm.nih.gov/pubmed/9175120

31. Yeni SN, Ozkara C, Buyru N, Baykara O, Hanoğlu L, Karaagac N, et al. Association between APOE polymorphisms and mesial temporal lobe epilepsy with hippocampal sclerosis. Eur J Neurol. 2005;12(2):103-7. http://doi.wiley.com/10.1111/j.1468-1331.2004.00956

32. Sporis D, Basic S, Sertić J, Mahovic Lakošić D, Babić T. Is apolipoprotein E ε2 associated with delayed onset of non-lesional temporal lobe epilepsy? Acta Clin Croat. 2017;56:10-4. https://doi.org/10.20471/acc.2017.56.01.02

33. Ng Y, McGregor AL, Duane DC, Jahneke HK, Bird CR, Whelless JW. Childhood mesial temporal sclerosis. J Child Neurol. 2006;21(6):512-7. http://journals.sagepub.com/doi/10.1177/088307380602100601

34. Fu Y, Lv R, Jin L, Lu Q, Shao X, He J, et al. Association of apolipoprotein E polymorphisms with temporal lobe epilepsy in a Chinese Han population. Epilepsy Res. 2010;91(2-3):253-9. http://linkinghub.elsevier.com/retrieve/pii/S092012111000207X

35. Polvikoski T, Sulkava R, Haltia M, Kainulainen K, Vuorio A, Verkoniemi A, et al. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N Engl J Med. 1995;333(19):1242-7. http://www.nejm.org/doi/abs/10.1056/NEJM199511093331902

36. Giray O, Ulgenalp A, Bora E, Uran N, Yilmaz E, Unalp A, et al. Role of apolipoprotein E in febrile convulsion. Pediatr Neurol. 2008;39(4):241-4. http://linkinghub.elsevier.com/retrieve/pii/S0887899408003056

37. Lavener P, Lavenex PB, Cachet F, Gehri M, Juvert T. No association between ApoE polymorphism and febrile seizures. Neurol Sci. 2016;37(1):31-6. http://link.springer.com/10.1007/s10072-015-2351-6

38. Lien E, Andersen GL, Bao Y, Gordish-Dressman H, Skranes JS, Vik T, et al. Apolipoprotein E polymorphisms and severity of cerebral palsy: a cross-sectional study in 255 children in Norway. Dev Med Child Neurol. 2013;55(4):372-7. http://doi.wiley.com/10.1111/dmcn.12086

39. Fagan AM, Holtzman DM, Munson G, Mathur T, Schneider D, Chang LK, et al. Unique lipoproteins secreted by primary
astrocytes from wild type, apoE (-/-), and human apoE transgenic mice. J Biol Chem. 1999;274(42):30001-7. http://www.ncbi.nlm.nih.gov/pubmed/10514484

40. Gong J-S, Kobayashi M, Hayashi H, Zou K, Sawamura N, Fujita SC, et al. Apolipoprotein E (ApoE) isoform-dependent lipid release from astrocytes prepared from human ApoE3 and ApoE4 knock-in mice. J Biol Chem. 2002;277(33):29919-26. http://www.jbc.orglookup/doi/10.1074/jbc.M20394200

41. Matsuda A, Nagao K, Matsuo M, Kioka N, Ueda K. 24(S)-hydroxycholesterol is actively eliminated from neuronal cells by ABCA1. J Neurochem. 2013;126(1):93-101. http://doi.wiley.com/10.1111/jnc.12275

42. Cedazo-Mínguez A. Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities. J Cell Mol Med. 2007;11(6):1227-38. http://doi.wiley.com/10.1111/j.1582-4934.2007.00130

43. Horsburgh K, McCarron MO, White F, Nicoll JA. The role of apolipoprotein E in Alzheimer's disease, acute brain injury and cerebrovascular disease: evidence of common mechanisms and utility of animal models. Neurobiol Aging.2000;21(2):245-55. http://www.ncbi.nlm.nih.gov/pubmed/10867209

Sažetak

POVEZANOST POLIMORFIZMA APOLIPOPROTEINA E I EPILEPSIJE U DJECE

M. Kukuruzović, V. Bašić Kes i M. Malenica

Apolipoprotein E (APOE) ima veliku ulogu u metabolizmu lipida i dokazan je čimbenik rizika za razvoj demencije i drugih neurodegenerativnih bolesti. Cilj istraživanja bio je utvrditi moguću povezanost pojedinih alela APOE, profila lipida u krvi i različitih tipova epilepsije u djece. Aleli APOE, kolesterol u krvi (ukupni kolesterol, lipoproteini visoke gustoće i lipoproteini niske gustoće (LDL)) te vrijednosti triglicerida analizirani su u uzorcima krvi kod 111 djece s epilepsijom i 118 djece podudarne dobi i spola bez epilepsije. Distribucija APOE genotipova bila je ista u djece obiju skupina. Značajno povišene razine ukupnog kolesterola i LDL kolesterola utvrđene su u kontrolnoj skupini (Z=3,49 odnosno 3,52, p<0,01). Nije pronađena statistički značajna razlika između genotipova djece s idiopatskom i simptomatskom epilepsijom (χ²=1,96; df=2; p>0,05). Postojale su statistički značajne razlike u razinama ukupnog kolesterola i LDL kolesterola utvrđene su u kontrolnoj skupini (Z=2,09; p<0,05) i LDL kolesterola (Z=2,05; p<0,05) ovisno o vrsti epilepsije u korist simptomatske epilepsije. Studija je potvrdila da ne postoji povezanost između APOE i tipa epilepsije u djece te je pokazala da djeca s epilepsijom imaju niži ukupni kolesterol i LDL kolesterol, ali je nađeno da djeca koja imaju simptomatsku epilepsiju imaju veću koncentraciju ukupnog i LDL kolesterola u odnosu na one s idiopatskom epilepsijom.

Ključne riječi: Apolipoprotein E; Plastičnost mozga; Djeca s epilepsijom; Polimorfizam gena; Lipoprotein